دورية أكاديمية
Association study of paroxetine therapeutic response with SERT gene polymorphisms in patients with major depressive disorder.
| العنوان: | Association study of paroxetine therapeutic response with SERT gene polymorphisms in patients with major depressive disorder. |
|---|---|
| المؤلفون: | Bozina N; Clinical Institute of Laboratory Diagnosis, Zagreb University School of Medicine and University Hospital Centre, Zagreb, Croatia. nbozina@net.hr, Peles AM, Sagud M, Bilusic H, Jakovljevic M |
| المصدر: | The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry [World J Biol Psychiatry] 2008; Vol. 9 (3), pp. 190-7. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Informa Healthcare Country of Publication: England NLM ID: 101120023 Publication Model: Print Cited Medium: Print ISSN: 1562-2975 (Print) Linking ISSN: 15622975 NLM ISO Abbreviation: World J Biol Psychiatry Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: London : Informa Healthcare Original Publication: Glasgow : WFSBP, 2000- |
| مواضيع طبية MeSH: | Depressive Disorder, Major/*drug therapy , Depressive Disorder, Major/*genetics , Paroxetine/*therapeutic use , Polymorphism, Genetic/*genetics , Serotonin Plasma Membrane Transport Proteins/*genetics , Selective Serotonin Reuptake Inhibitors/*therapeutic use, DNA Primers/genetics ; Diagnostic and Statistical Manual of Mental Disorders ; Female ; Humans ; Male ; Middle Aged ; Minisatellite Repeats/genetics |
| مستخلص: | We investigated the relationships between LS promoter (SERTPR) and ls intron2 (SERTin2) genetic variants of serotonin transporter (SERT) polymorphisms with treatment response in 130 patients with major depressive disorder (MDD) treated with paroxetine (20 mg/day) for 6 weeks. To assess and evaluate therapeutic response to paroxetine all patients were rated weekly using the HAMD-17 scale. Responders were defined as those subjects with a decrease in HAMD scale by > or = 50% at week 6 of treatment. Comparison of genotypes and alleles frequency of the SERTPR between responders and nonresponders revealed significant differences among genotypes and overrepresentation of the S allele in the group of non-responders (P = 0.0004). SERTin2-ss genotype bearing subjects showed better treatment response compared to ls and ll genotype from the fourth week of treatment (P = 0.035). Statistical differences were also found in distributions of the estimated haplotypes between responders and non-responders, while subsequent analysis revealed overrepresentation of S/l haplotype (P = 0.006) in the group of non-responders. SERTPR and SERTin2 were found to be in linkage disequilibrium in studied population. These findings identify genetic factors associated with paroxetine treatment response in MDD patients. |
| المشرفين على المادة: | 0 (DNA Primers) 0 (SLC6A4 protein, human) 0 (Serotonin Plasma Membrane Transport Proteins) 0 (Serotonin Uptake Inhibitors) 41VRH5220H (Paroxetine) |
| تواريخ الأحداث: | Date Created: 20070914 Date Completed: 20090114 Latest Revision: 20221207 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1080/15622970701308397 |
| PMID: | 17853254 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher | تدمد: | 1562-2975 |
|---|---|
| DOI: | 10.1080/15622970701308397 |